The Impact of New Coronavirus on Cancer Patients
-
Aida Karimian
,
Sona Talaei
,
Arash Abdolmaleki
,
Asadollah Asadi
,
Muhammad Akram
,
Hussein A. Ghanimi
Abstract
At the end of 2019, a new coronavirus (severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) emerged in China and then spread worldwide. Presently, Coronavirus Disease 2019 (COVID-19) is a main public health issue. As of August 2021, more than 200 million confirmed cases from coronavirus and more than 4 million deaths have been reported by WHO in 222 countries. The data sources are Google Scholar, PubMed, and Science Direct articles. Publications were searched without regard to time in order to obtain a holistic and comprehensive perspective of the research done on this issue thus far. The SARS-CoV-2 can be transmitted from the human-to-human by respiratory droplets and shows great potential for a pandemic. Therefore, on March 11, 2020, COVID-19 was introduced as a global pandemic by WHO. Cancer patients are at high risk for exposure to the coronavirus. In the present article, we discuss the impact of the COVID-19 pandemic on the quality of life of cancer patients and their treatment process. One of these challenges is not visiting the patients in medical centers and hospitals for afraid of contracting the virus. Therefore, the diagnosis and treatment of cancer patients may be delayed, which is a serious threat to the lives of cancer patients. In this article, in addition to the impact of coronavirus on the lives of cancer patients, the severity of the disease in these patients, their required medical care, and the vaccination process are discussed.
1. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health 2020;25(3):278-280.
2. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020;215:108427.
3. Hasanzadeh A, Alamdaran M, Ahmadi S, et al. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies. J Control Release 2021;336:354-374.
4. Liu J, Liu Y, Xiang P, Pu L, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020;18(1):206.
5. Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. J Formos Med Assoc 2020;119(3):670-673.
6. Bryson WJ. Long-term health-related quality of life concerns related to the COVID-19 pandemic: a call to action. Qual Life Res 2021;30(3):643-645.
7. Vrdoljak E, Sullivan R, Lawler M. Cancer and coronavirus disease 2019; how do we manage cancer optimally through a public health crisis? Eur J Cancer 2020;132:98-99.
8. enkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. medRxiv [Preprint]. 2020:2020.05.27.20115303.
9. Abdolmaleki A, Asadi A, Gurushankar K, Karimi Shayan T, Abedi Sarvestani F. Importance of Nano Medicine and New Drug Therapies for Cancer. Adv Pharm Bull. 2021;11(3):450-457.
10. Hoda W, Bharati S, Kumar A, Choudhary P, Shankar A. Socio-Cultural and Economic Impact of Corona Virus on Cancer Patients, Caregivers and Survivors. Asian Pacific Journal of Cancer Care 2020; 5(S1):171-173.
11. Al-Quteimat OM, Amer AM. The Impact of the COVID-19 Pandemic on Cancer Patients. Am J Clin Oncol 2020;43(6):452-455.
12. Rashidi S, Asadi A, Abdolmaleki A. Cancer Stem Cells: A Narrative Review. Journal of Rafsanjan University of Medical Sciences 2021;20(2):201-226.
13. Tougeron D, Hentzien M, Seitz-Polski B, et al. Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). Eur J Cancer 2021;150: 232-239.
14. Wang Q, Berger NA, Xu R. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. JAMA Oncol 2021;7(2):220-227.
15. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507-513.
16. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20(6): 669-77.
17. Cannistra SA, Haffty BG, Ballman K. Challenges Faced by Medical Journals During the COVID-19 Pandemic. J Clin Oncol 2020;38(19): 2206-7.
18. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020; 10(6):783-91.
19. Rogado J, Obispo B, Pangua C, et al. Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. Clin Transl Oncol 2020; 22(12): 2364-2368.
20. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335-337.
21. Chen P, Mao L, Nassis GP, Harmer P, Ainsworth BE, Li F. Coronavirus disease (COVID-19): The need to maintain regular physical activity while taking precautions. J Sport Health Sci 2020;9(2):103-104.
22. Hall G, Laddu DR, Phillips SA, Lavie CJ, Arena R. A tale of two pandemics: How will COVID-19 and global trends in physical inactivity and sedentary behavior affect one another? Prog Cardiovasc Dis 2021;64:108-110.
23. Balanzá-Martínez V, Atienza-Carbonell B, Kapczinski F, De Boni RB. Lifestyle behaviours during the COVID-19 - time to connect. Acta Psychiatr Scand 2020;141(5):399-400.
24. Ciążyńska M, Pabianek M, Szczepaniak K, et al. Quality of life of cancer patients during coronavirus disease (COVID-19) pandemic. Psychooncology 2020;29(9):1377-1379.
25. Torales J, O'Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry 2020;66(4):317-320.
26. Thaler M, Khosravi I, Leithner A, Papagelopoulos PJ, Ruggieri P. Impact of the COVID-19 pandemic on patients suffering from musculoskeletal tumours. Int Orthop 2020;44(8):1503-1509.
• 27. Van De Poll-franse LV, de Rooij B, Horevoorts N, et al. 1686P The impact of the COVID-19 crisis on perceived changes in care and wellbeing of cancer patients and norm participants: Results of the PROFILES registry. Annals of Oncology 2020; 31: S997.
28. Juanjuan L, Santa-Maria CA, Hongfang F, et al. Patient-reported Outcomes of Patients With Breast Cancer During the COVID-19 Outbreak in the Epicenter of China: A Cross-sectional Survey Study. Clin Breast Cancer 2020;20(5): e651-e662.
29. Frey MK, Ellis AE, Zeligs K, et al. Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer. Am J Obstet Gynecol 2020; 223(5):725.e1-725.e9.
30. Romito F, Dellino M, Loseto G, et al. Psychological Distress in Outpatients With Lymphoma During the COVID-19 Pandemic. Front Oncol 2020;10:1270.
31. Younger E, Smrke A, Lidington E, et al. Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic. Cancers (Basel) 2020;12(8):2288..
32. Rakhsha A, Azghandi S, Taghizadeh-Hesary F. Decision on Chemotherapy Amidst COVID-19 Pandemic: a Review and a Practical Approach from Iran. Infect Chemother 2020;52(4):496-502.
33. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020; 395(10241):1919-1926.
34. Zhang H, Wang L, Chen Y, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer 2020;126(17):4023-4031.
35. Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 Outcomes in Patients With Cancer. J Clin Oncol 2020;38(30): 3538-3546.
36. Luo B, Li J, Hou X, Yang Q, et al. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination. Future Oncol 2021;17(26):3477-3484.
37. Waris A, Din M, Khalid A, et al. Evaluation of hematological parameters as an indicator of disease severity in Covid-19 patients: Pakistan's experience. J Clin Lab Anal 2021;35(6):e23809.
38. Li J, Huang DQ, Zou B, et al. Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes. J Med Virol 2021;93(3):1449-1458.
39. Jazieh AR, Akbulut H, Curigliano G, et al. Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. JCO Glob Oncol 2020;6:1428-1438.
40. Jazieh AR, Coutinho AK, Bensalem AA, et al. Impact of the COVID-19 Pandemic on Oncologists: Results of an International Study. JCO Glob Oncol 2021;7:242-252..
41. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic. N Engl J Med 2020;382(18):e41.
42. Gondi S, Beckman AL, Deveau N, et al. Personal protective equipment needs in the USA during the COVID-19 pandemic. Lancet 2020;395(10237):e90-e91.
43. Livingston E, Desai A, Berkwits M. Sourcing Personal Protective Equipment During the COVID-19 Pandemic. JAMA 2020;323(19):1912-1914.
44. Bauchner H, Fontanarosa PB, Livingston EH. Conserving Supply of Personal Protective Equipment-A Call for Ideas. JAMA 2020;323(19):1911.
45. Qian X, Ren R, Wang Y, et al; Members of Steering Committee, Society of Global Health, Chinese Preventive Medicine Association. Fighting against the common enemy of COVID-19: a practice of building a community with a shared future for mankind. Infect Dis Poverty 2020;9(1):34.
46. Ueda M, Martins R, Hendrie PC, et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Compr Canc Netw 2020:1-4.
47. Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020;21(4):e180.
48. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020;21(4):e181.
49. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239-1242.
50. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020;55(5):105938.
51. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71(15):732-739.
52. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56(1):105949.
53. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269-271.
54. Wu Z, Zhang Q, Gong X, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ 2020;192(27):E734-E744.
55. Tong S, Su Y, Yu Y, et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents 2020;56(3):106114.
56. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395(10238): 1695-1704.
57. Nourian A, Khalili H. Sofosbuvir as a potential option for the treatment of COVID-19. Acta Biomed 2020;91(2):236-238.
58. Kelleni MT. Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacol Res 2020;157:104874.
59. Deftereos SG, Siasos G, Giannopoulos G, et al. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design. Hellenic J Cardiol 2020;61(1):42-45.
60. Budhathoki P, Shrestha DB, Rawal E, Khadka S. Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis. SN Compr Clin Med 2020:1-21.
61. Mohtadi N, Ghaysouri A, Shirazi S, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series. Virology 2020;548:1-5.
62. Najar Nobari N, Seirafianpour F, Mashayekhi F, Goodarzi A. A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. Dermatol Ther 2021;34(1):e14662.
63. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181(2):271-280.e8.
64. Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 2020;30(4):343-355.
65. Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020;253:117592.
66. Gimeno A, Mestres-Truyol J, Ojeda-Montes MJ, et al. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. Int J Mol Sci 2020;21(11):3793.
67. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020;10(5): 766-788.
68. Wu Q, Fan X, Hong H, et al. Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspective. Food Chem Toxicol 2020;145: 111767.
69. Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review. J Am Acad Dermatol 2020;83(2):563-578.
70. Sharma A, Vora R, Modi M, Sharma A, Marfatia Y. Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol 2008;74(3):234-7.
71. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020:S0140-6736(20)31180-6.
72. Plaze M, Attali D, Petit AC, et al. Repurposing chlorpromazine to treat COVID-19: The reCoVery study. Encephale 2020;46(3):169-172.
73. Nobile B, Durand M, Courtet P, et al. Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2? Schizophr Res 2020;223:373-375.
74. Huang L, Chen Y, Xiao J, et al. Progress in the Research and Development of Anti-COVID-19 Drugs. Front Public Health 2020;8:365.
75. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020;395(10223):e30-e31.
76. Praveen D, Puvvada RC, M VA. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int J Antimicrob Agents 2020;55(5):105967.
77. Peterson D, Damsky W, King B. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Am Acad Dermatol 2020;82(6):e223-e226.
78. Türsen Ü, Türsen B, Lotti T. Cutaneous sıde-effects of the potential COVID-19 drugs. Dermatol Ther 2020;33(4):e13476.
79. Le Cleach L, Dousset L, Assier H, et al. Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on polymerase chain reaction and serology testing. Br J Dermatol 2020;183(5):866-874.
80. Freeman EE, McMahon DE, Lipoff JB, et al. Cold and COVID: recurrent pernio during the COVID-19 pandemic. Br J Dermatol 2021;185(1):214-216.
81. Aygün İ, Kaya M, Alhajj R. Identifying side effects of commonly used drugs in the treatment of Covid 19. Sci Rep 2020;10(1):21508.
82. Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. Psychopharmacology of COVID-19. Psychosomatics 2020;61(5):411-427.
83. Wang J, Peng Y, Xu H, Cui Z, Williams RO 3rd. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech 2020;21(6):225.
84. Zheng Z, Diaz-Arévalo D, Guan H, Zeng M. Noninvasive vaccination against infectious diseases. Hum Vaccin Immunother 2018;14(7):1717-1733.
85. Dai H, Han J, Lichtfouse E. Who is running faster, the virus or the vaccine? Environ Chem Lett 2020:1-6. doi: 10.1007/s10311-020-01110-w. Epub ahead of print.
86. Dutta AK. Vaccine Against Covid-19 Disease - Present Status of Development. Indian J Pediatr 2020;87(10):810-816. doi: 10.1007/s12098-020-03475-w. Epub 2020 Sep 3.
87. CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep 2021;70(21):792-793.
88. Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med 2021;10(7):1428.
89. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31(7):894-901.
2. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020;215:108427.
3. Hasanzadeh A, Alamdaran M, Ahmadi S, et al. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies. J Control Release 2021;336:354-374.
4. Liu J, Liu Y, Xiang P, Pu L, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020;18(1):206.
5. Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. J Formos Med Assoc 2020;119(3):670-673.
6. Bryson WJ. Long-term health-related quality of life concerns related to the COVID-19 pandemic: a call to action. Qual Life Res 2021;30(3):643-645.
7. Vrdoljak E, Sullivan R, Lawler M. Cancer and coronavirus disease 2019; how do we manage cancer optimally through a public health crisis? Eur J Cancer 2020;132:98-99.
8. enkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. medRxiv [Preprint]. 2020:2020.05.27.20115303.
9. Abdolmaleki A, Asadi A, Gurushankar K, Karimi Shayan T, Abedi Sarvestani F. Importance of Nano Medicine and New Drug Therapies for Cancer. Adv Pharm Bull. 2021;11(3):450-457.
10. Hoda W, Bharati S, Kumar A, Choudhary P, Shankar A. Socio-Cultural and Economic Impact of Corona Virus on Cancer Patients, Caregivers and Survivors. Asian Pacific Journal of Cancer Care 2020; 5(S1):171-173.
11. Al-Quteimat OM, Amer AM. The Impact of the COVID-19 Pandemic on Cancer Patients. Am J Clin Oncol 2020;43(6):452-455.
12. Rashidi S, Asadi A, Abdolmaleki A. Cancer Stem Cells: A Narrative Review. Journal of Rafsanjan University of Medical Sciences 2021;20(2):201-226.
13. Tougeron D, Hentzien M, Seitz-Polski B, et al. Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). Eur J Cancer 2021;150: 232-239.
14. Wang Q, Berger NA, Xu R. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. JAMA Oncol 2021;7(2):220-227.
15. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507-513.
16. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20(6): 669-77.
17. Cannistra SA, Haffty BG, Ballman K. Challenges Faced by Medical Journals During the COVID-19 Pandemic. J Clin Oncol 2020;38(19): 2206-7.
18. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020; 10(6):783-91.
19. Rogado J, Obispo B, Pangua C, et al. Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. Clin Transl Oncol 2020; 22(12): 2364-2368.
20. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335-337.
21. Chen P, Mao L, Nassis GP, Harmer P, Ainsworth BE, Li F. Coronavirus disease (COVID-19): The need to maintain regular physical activity while taking precautions. J Sport Health Sci 2020;9(2):103-104.
22. Hall G, Laddu DR, Phillips SA, Lavie CJ, Arena R. A tale of two pandemics: How will COVID-19 and global trends in physical inactivity and sedentary behavior affect one another? Prog Cardiovasc Dis 2021;64:108-110.
23. Balanzá-Martínez V, Atienza-Carbonell B, Kapczinski F, De Boni RB. Lifestyle behaviours during the COVID-19 - time to connect. Acta Psychiatr Scand 2020;141(5):399-400.
24. Ciążyńska M, Pabianek M, Szczepaniak K, et al. Quality of life of cancer patients during coronavirus disease (COVID-19) pandemic. Psychooncology 2020;29(9):1377-1379.
25. Torales J, O'Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry 2020;66(4):317-320.
26. Thaler M, Khosravi I, Leithner A, Papagelopoulos PJ, Ruggieri P. Impact of the COVID-19 pandemic on patients suffering from musculoskeletal tumours. Int Orthop 2020;44(8):1503-1509.
• 27. Van De Poll-franse LV, de Rooij B, Horevoorts N, et al. 1686P The impact of the COVID-19 crisis on perceived changes in care and wellbeing of cancer patients and norm participants: Results of the PROFILES registry. Annals of Oncology 2020; 31: S997.
28. Juanjuan L, Santa-Maria CA, Hongfang F, et al. Patient-reported Outcomes of Patients With Breast Cancer During the COVID-19 Outbreak in the Epicenter of China: A Cross-sectional Survey Study. Clin Breast Cancer 2020;20(5): e651-e662.
29. Frey MK, Ellis AE, Zeligs K, et al. Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer. Am J Obstet Gynecol 2020; 223(5):725.e1-725.e9.
30. Romito F, Dellino M, Loseto G, et al. Psychological Distress in Outpatients With Lymphoma During the COVID-19 Pandemic. Front Oncol 2020;10:1270.
31. Younger E, Smrke A, Lidington E, et al. Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic. Cancers (Basel) 2020;12(8):2288..
32. Rakhsha A, Azghandi S, Taghizadeh-Hesary F. Decision on Chemotherapy Amidst COVID-19 Pandemic: a Review and a Practical Approach from Iran. Infect Chemother 2020;52(4):496-502.
33. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020; 395(10241):1919-1926.
34. Zhang H, Wang L, Chen Y, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer 2020;126(17):4023-4031.
35. Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 Outcomes in Patients With Cancer. J Clin Oncol 2020;38(30): 3538-3546.
36. Luo B, Li J, Hou X, Yang Q, et al. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination. Future Oncol 2021;17(26):3477-3484.
37. Waris A, Din M, Khalid A, et al. Evaluation of hematological parameters as an indicator of disease severity in Covid-19 patients: Pakistan's experience. J Clin Lab Anal 2021;35(6):e23809.
38. Li J, Huang DQ, Zou B, et al. Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes. J Med Virol 2021;93(3):1449-1458.
39. Jazieh AR, Akbulut H, Curigliano G, et al. Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. JCO Glob Oncol 2020;6:1428-1438.
40. Jazieh AR, Coutinho AK, Bensalem AA, et al. Impact of the COVID-19 Pandemic on Oncologists: Results of an International Study. JCO Glob Oncol 2021;7:242-252..
41. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic. N Engl J Med 2020;382(18):e41.
42. Gondi S, Beckman AL, Deveau N, et al. Personal protective equipment needs in the USA during the COVID-19 pandemic. Lancet 2020;395(10237):e90-e91.
43. Livingston E, Desai A, Berkwits M. Sourcing Personal Protective Equipment During the COVID-19 Pandemic. JAMA 2020;323(19):1912-1914.
44. Bauchner H, Fontanarosa PB, Livingston EH. Conserving Supply of Personal Protective Equipment-A Call for Ideas. JAMA 2020;323(19):1911.
45. Qian X, Ren R, Wang Y, et al; Members of Steering Committee, Society of Global Health, Chinese Preventive Medicine Association. Fighting against the common enemy of COVID-19: a practice of building a community with a shared future for mankind. Infect Dis Poverty 2020;9(1):34.
46. Ueda M, Martins R, Hendrie PC, et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Compr Canc Netw 2020:1-4.
47. Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020;21(4):e180.
48. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020;21(4):e181.
49. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239-1242.
50. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020;55(5):105938.
51. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71(15):732-739.
52. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56(1):105949.
53. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269-271.
54. Wu Z, Zhang Q, Gong X, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ 2020;192(27):E734-E744.
55. Tong S, Su Y, Yu Y, et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents 2020;56(3):106114.
56. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395(10238): 1695-1704.
57. Nourian A, Khalili H. Sofosbuvir as a potential option for the treatment of COVID-19. Acta Biomed 2020;91(2):236-238.
58. Kelleni MT. Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacol Res 2020;157:104874.
59. Deftereos SG, Siasos G, Giannopoulos G, et al. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design. Hellenic J Cardiol 2020;61(1):42-45.
60. Budhathoki P, Shrestha DB, Rawal E, Khadka S. Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis. SN Compr Clin Med 2020:1-21.
61. Mohtadi N, Ghaysouri A, Shirazi S, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series. Virology 2020;548:1-5.
62. Najar Nobari N, Seirafianpour F, Mashayekhi F, Goodarzi A. A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. Dermatol Ther 2021;34(1):e14662.
63. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181(2):271-280.e8.
64. Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 2020;30(4):343-355.
65. Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020;253:117592.
66. Gimeno A, Mestres-Truyol J, Ojeda-Montes MJ, et al. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. Int J Mol Sci 2020;21(11):3793.
67. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020;10(5): 766-788.
68. Wu Q, Fan X, Hong H, et al. Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspective. Food Chem Toxicol 2020;145: 111767.
69. Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review. J Am Acad Dermatol 2020;83(2):563-578.
70. Sharma A, Vora R, Modi M, Sharma A, Marfatia Y. Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol 2008;74(3):234-7.
71. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020:S0140-6736(20)31180-6.
72. Plaze M, Attali D, Petit AC, et al. Repurposing chlorpromazine to treat COVID-19: The reCoVery study. Encephale 2020;46(3):169-172.
73. Nobile B, Durand M, Courtet P, et al. Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2? Schizophr Res 2020;223:373-375.
74. Huang L, Chen Y, Xiao J, et al. Progress in the Research and Development of Anti-COVID-19 Drugs. Front Public Health 2020;8:365.
75. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020;395(10223):e30-e31.
76. Praveen D, Puvvada RC, M VA. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int J Antimicrob Agents 2020;55(5):105967.
77. Peterson D, Damsky W, King B. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Am Acad Dermatol 2020;82(6):e223-e226.
78. Türsen Ü, Türsen B, Lotti T. Cutaneous sıde-effects of the potential COVID-19 drugs. Dermatol Ther 2020;33(4):e13476.
79. Le Cleach L, Dousset L, Assier H, et al. Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on polymerase chain reaction and serology testing. Br J Dermatol 2020;183(5):866-874.
80. Freeman EE, McMahon DE, Lipoff JB, et al. Cold and COVID: recurrent pernio during the COVID-19 pandemic. Br J Dermatol 2021;185(1):214-216.
81. Aygün İ, Kaya M, Alhajj R. Identifying side effects of commonly used drugs in the treatment of Covid 19. Sci Rep 2020;10(1):21508.
82. Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. Psychopharmacology of COVID-19. Psychosomatics 2020;61(5):411-427.
83. Wang J, Peng Y, Xu H, Cui Z, Williams RO 3rd. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech 2020;21(6):225.
84. Zheng Z, Diaz-Arévalo D, Guan H, Zeng M. Noninvasive vaccination against infectious diseases. Hum Vaccin Immunother 2018;14(7):1717-1733.
85. Dai H, Han J, Lichtfouse E. Who is running faster, the virus or the vaccine? Environ Chem Lett 2020:1-6. doi: 10.1007/s10311-020-01110-w. Epub ahead of print.
86. Dutta AK. Vaccine Against Covid-19 Disease - Present Status of Development. Indian J Pediatr 2020;87(10):810-816. doi: 10.1007/s12098-020-03475-w. Epub 2020 Sep 3.
87. CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep 2021;70(21):792-793.
88. Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med 2021;10(7):1428.
89. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31(7):894-901.
| Files | ||
| Issue | Vol 9, No 4 (Autumn 2021) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/jpc.v9i4.8226 | |
| Keywords | ||
| Coronaviruse SARS-CoV-2 COVID-19 Cancer | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Karimian A, Talaei S, Abdolmaleki A, Asadi A, Akram M, A. Ghanimi H. The Impact of New Coronavirus on Cancer Patients. J Pharm Care. 2021;9(4):209-226.
